デフォルト表紙
市場調査レポート
商品コード
1413091

ナノメディシンの市場:分子タイプ、モダリティ、用途、適応症別-2024-2030年の世界予測

Nanomedicine Market by Molecule Type (Nanodevices, Nanoparticles, Nanoshells), Modality (Diagnostics, Treatment), Application, Indication - Global Forecast 2024-2030

出版日: | 発行: 360iResearch | ページ情報: 英文 180 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=159.45円
ナノメディシンの市場:分子タイプ、モダリティ、用途、適応症別-2024-2030年の世界予測
出版日: 2024年01月15日
発行: 360iResearch
ページ情報: 英文 180 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

ナノメディシン市場規模は2023年に2,062億5,000万米ドルと推定され、2024年には2,273億7,000万米ドルに達し、CAGR 10.91%で2030年には4,258億8,000万米ドルに達すると予測されます。

世界のナノメディシン市場

主な市場の統計
基準年[2023] 2,062億5,000万米ドル
予測年[2024] 2,273億7,000万米ドル
予測年 [2030] 4,258億8,000万米ドル
CAGR(%) 10.91%
ナノメディシン Market-IMG1

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスはナノメディシン市場を評価する上で極めて重要です。事業戦略や製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます:フォアフロント(F)、パスファインダー(P)、ニッチ(N)、バイタル(V)です。

市場シェア分析

市場シェア分析は、ナノメディシン市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています:

1-市場の浸透度:主要企業が提供する市場に関する包括的な情報を提示しています。

2-市場の開拓度:有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3-市場の多様化:新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4-競合の評価と情報:市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5-製品開発およびイノベーション:将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています:

1-ナノメディシン市場の市場規模および予測は?

2-ナノメディシン市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か?

3-ナノメディシン市場における技術動向と規制の枠組みは?

4-ナノメディシン市場における主要ベンダーの市場シェアは?

5-ナノメディシン市場への参入に適した形態や戦略的手段は?

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 慢性疾患の蔓延と効率的な治療の必要性
      • ナノメディシン技術の個別化医療への活用
      • 体外診断および生体内イメージングへの応用
    • 抑制要因
      • ナノメディシンの開発と商品化には高額な費用がかかる
    • 機会
      • 斬新なナノメディシン開発のための戦略的提携
      • ナノメディシンの研究開発に有利な資金情勢
    • 課題
      • 入手可能な臨床証拠が限られている
  • 市場セグメンテーション分析
  • 市場動向分析
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み

第6章 ナノメディシンの市場分子の種類別

  • ナノデバイス
  • ナノ粒子
    • デンドリマー
    • ヒドロゲルナノ粒子
    • 無機ナノ粒子
    • リポソーム
    • 金属および金属酸化物のナノ粒子
    • ポリマーおよびポリマー薬物複合体
  • ナノシェル
  • ナノチューブ

第7章 ナノメディシンの市場:モダリティ別

  • 診断
  • 処理

第8章 ナノメディシンの市場:用途別

  • 画像診断
  • ドラッグデリバリー
  • インプラント
  • 再生医療
  • ワクチン

第9章 ナノメディシンの市場適応症別

  • 臨床循環器学
  • 臨床腫瘍学
  • 免疫学
  • 感染症
  • 神経内科
  • 眼科
  • 整形外科
  • 泌尿器科

第10章 南北アメリカのナノメディシンの市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第11章 アジア太平洋地域のナノメディシンの市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第12章 欧州・中東・アフリカのナノメディシンの市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第13章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析:主要企業別
  • 競合シナリオ主要企業別の分析

第14章 競争力のあるポートフォリオ

  • 主要な企業プロファイル
    • AMAG Pharmaceuticals, Inc.
    • Amgen Inc.
    • Arrowhead Pharmaceuticals, Inc.
    • Bausch Health Companies Inc.
    • Bayer Healthcare
    • Biogen Inc.
    • Bristol-Myers Squibb Company
    • Celgene Corporation
    • Eisai Co Ltd
    • F. Hoffmann-La Roche AG
    • Galen Ltd
    • General Electric Company
    • Gilead Sciences, Inc.
    • Ipsen SA
    • Jazz Pharmaceuticals plc
    • Lantheus Holdings, Inc.
    • Leadient BioSciences Inc.
    • Mallinckrodt Pharmaceuticals
    • Merck & Co., Inc.
    • Nano spectra Biosciences, Inc.
    • Novo Nordisk A/S
    • OSARTIS GmbH
    • Pacira BioSciences Inc.
    • Pfizer Inc.
    • Sanofi S.A.
    • Taiwan Liposome Company, Ltd.
    • Takeda Pharmaceutical Company Limited
    • Teva Pharmaceuticals Ltd.
    • UCB SA
    • Zimmer Biomet Holdings, Inc.
  • 主要な製品ポートフォリオ

第15章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. NANOMEDICINE MARKET RESEARCH PROCESS
  • FIGURE 2. NANOMEDICINE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. NANOMEDICINE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. NANOMEDICINE MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. NANOMEDICINE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. NANOMEDICINE MARKET DYNAMICS
  • FIGURE 7. NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2023 VS 2030 (%)
  • FIGURE 8. NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. NANOMEDICINE MARKET SIZE, BY MODALITY, 2023 VS 2030 (%)
  • FIGURE 10. NANOMEDICINE MARKET SIZE, BY MODALITY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. NANOMEDICINE MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 12. NANOMEDICINE MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. NANOMEDICINE MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 14. NANOMEDICINE MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS NANOMEDICINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS NANOMEDICINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES NANOMEDICINE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES NANOMEDICINE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC NANOMEDICINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC NANOMEDICINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA NANOMEDICINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA NANOMEDICINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. NANOMEDICINE MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 24. NANOMEDICINE MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. NANOMEDICINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. NANOMEDICINE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL NANOMEDICINE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 6. NANOMEDICINE MARKET SIZE, BY NANODEVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 9. NANOMEDICINE MARKET SIZE, BY DENDRIMERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. NANOMEDICINE MARKET SIZE, BY HYDROGEL NANOPARTICLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. NANOMEDICINE MARKET SIZE, BY INORGANIC NANOPARTICLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. NANOMEDICINE MARKET SIZE, BY LIPOSOMES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. NANOMEDICINE MARKET SIZE, BY METAL & METAL OXIDE NANOPARTICLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. NANOMEDICINE MARKET SIZE, BY POLYMERS & POLYMER DRUG CONJUGATES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. NANOMEDICINE MARKET SIZE, BY NANOSHELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. NANOMEDICINE MARKET SIZE, BY NANOTUBES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 18. NANOMEDICINE MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. NANOMEDICINE MARKET SIZE, BY TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 21. NANOMEDICINE MARKET SIZE, BY DIAGNOSTIC IMAGING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. NANOMEDICINE MARKET SIZE, BY DRUG DELIVERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. NANOMEDICINE MARKET SIZE, BY IMPLANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. NANOMEDICINE MARKET SIZE, BY REGENERATIVE MEDICINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. NANOMEDICINE MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 27. NANOMEDICINE MARKET SIZE, BY CLINICAL CARDIOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. NANOMEDICINE MARKET SIZE, BY CLINICAL ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. NANOMEDICINE MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. NANOMEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. NANOMEDICINE MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. NANOMEDICINE MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. NANOMEDICINE MARKET SIZE, BY ORTHOPEDICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. NANOMEDICINE MARKET SIZE, BY UROLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS NANOMEDICINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 48. BRAZIL NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 49. BRAZIL NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. BRAZIL NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. CANADA NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 53. CANADA NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 54. CANADA NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. CANADA NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. MEXICO NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 58. MEXICO NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 59. MEXICO NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. MEXICO NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 63. UNITED STATES NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 64. UNITED STATES NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. UNITED STATES NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 66. UNITED STATES NANOMEDICINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC NANOMEDICINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 73. AUSTRALIA NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. AUSTRALIA NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 75. AUSTRALIA NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 76. AUSTRALIA NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. AUSTRALIA NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 78. CHINA NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. CHINA NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 80. CHINA NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 81. CHINA NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. CHINA NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 83. INDIA NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. INDIA NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 85. INDIA NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 86. INDIA NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. INDIA NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 88. INDONESIA NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. INDONESIA NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 90. INDONESIA NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 91. INDONESIA NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. INDONESIA NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 93. JAPAN NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. JAPAN NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 95. JAPAN NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 96. JAPAN NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. JAPAN NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 98. MALAYSIA NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. MALAYSIA NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 100. MALAYSIA NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 101. MALAYSIA NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. MALAYSIA NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 103. PHILIPPINES NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. PHILIPPINES NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 105. PHILIPPINES NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 106. PHILIPPINES NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 107. PHILIPPINES NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 108. SINGAPORE NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. SINGAPORE NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 110. SINGAPORE NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 111. SINGAPORE NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 112. SINGAPORE NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 113. SOUTH KOREA NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. SOUTH KOREA NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 115. SOUTH KOREA NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 116. SOUTH KOREA NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. SOUTH KOREA NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 118. TAIWAN NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. TAIWAN NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 120. TAIWAN NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 121. TAIWAN NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 122. TAIWAN NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 123. THAILAND NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. THAILAND NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 125. THAILAND NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 126. THAILAND NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 127. THAILAND NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 128. VIETNAM NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. VIETNAM NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 130. VIETNAM NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 131. VIETNAM NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. VIETNAM NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA NANOMEDICINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 139. DENMARK NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. DENMARK NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 141. DENMARK NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 142. DENMARK NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 143. DENMARK NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 144. EGYPT NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. EGYPT NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 146. EGYPT NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 147. EGYPT NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 148. EGYPT NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 149. FINLAND NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. FINLAND NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 151. FINLAND NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 152. FINLAND NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 153. FINLAND NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 154. FRANCE NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. FRANCE NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 156. FRANCE NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 157. FRANCE NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 158. FRANCE NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 159. GERMANY NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. GERMANY NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 161. GERMANY NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 162. GERMANY NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 163. GERMANY NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 164. ISRAEL NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. ISRAEL NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 166. ISRAEL NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 167. ISRAEL NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 168. ISRAEL NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 169. ITALY NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. ITALY NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 171. ITALY NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 172. ITALY NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 173. ITALY NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 174. NETHERLANDS NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. NETHERLANDS NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 176. NETHERLANDS NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 177. NETHERLANDS NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 178. NETHERLANDS NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 179. NIGERIA NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. NIGERIA NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 181. NIGERIA NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 182. NIGERIA NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 183. NIGERIA NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 184. NORWAY NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. NORWAY NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 186. NORWAY NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 187. NORWAY NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 188. NORWAY NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 189. POLAND NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. POLAND NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 191. POLAND NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 192. POLAND NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 193. POLAND NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 194. QATAR NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. QATAR NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 196. QATAR NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 197. QATAR NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 198. QATAR NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 199. RUSSIA NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 200. RUSSIA NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 201. RUSSIA NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 202. RUSSIA NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 203. RUSSIA NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 204. SAUDI ARABIA NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 205. SAUDI ARABIA NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 206. SAUDI ARABIA NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 207. SAUDI ARABIA NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 208. SAUDI ARABIA NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 209. SOUTH AFRICA NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 210. SOUTH AFRICA NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 211. SOUTH AFRICA NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 212. SOUTH AFRICA NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 213. SOUTH AFRICA NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 214. SPAIN NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 215. SPAIN NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 216. SPAIN NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 217. SPAIN NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 218. SPAIN NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 219. SWEDEN NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 220. SWEDEN NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 221. SWEDEN NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 222. SWEDEN NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 223. SWEDEN NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 224. SWITZERLAND NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 225. SWITZERLAND NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 226. SWITZERLAND NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 227. SWITZERLAND NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 228. SWITZERLAND NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 229. TURKEY NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 230. TURKEY NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 231. TURKEY NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 232. TURKEY NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 233. TURKEY NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED ARAB EMIRATES NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED ARAB EMIRATES NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED ARAB EMIRATES NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED ARAB EMIRATES NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 238. UNITED ARAB EMIRATES NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 239. UNITED KINGDOM NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 240. UNITED KINGDOM NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 241. UNITED KINGDOM NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 242. UNITED KINGDOM NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 243. UNITED KINGDOM NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 244. NANOMEDICINE MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 245. NANOMEDICINE MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 246. NANOMEDICINE MARKET LICENSE & PRICING
目次
Product Code: MRR-C002B1C9958A

[180 Pages Report] The Nanomedicine Market size was estimated at USD 206.25 billion in 2023 and expected to reach USD 227.37 billion in 2024, at a CAGR 10.91% to reach USD 425.88 billion by 2030.

Global Nanomedicine Market

KEY MARKET STATISTICS
Base Year [2023] USD 206.25 billion
Estimated Year [2024] USD 227.37 billion
Forecast Year [2030] USD 425.88 billion
CAGR (%) 10.91%
Nanomedicine Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Nanomedicine Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Nanomedicine Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Nanomedicine Market, highlighting leading vendors and their innovative profiles. These include AMAG Pharmaceuticals, Inc., Amgen Inc., Arrowhead Pharmaceuticals, Inc., Bausch Health Companies Inc., Bayer Healthcare, Biogen Inc., Bristol-Myers Squibb Company, Celgene Corporation, Eisai Co Ltd, F. Hoffmann-La Roche AG, Galen Ltd, General Electric Company, Gilead Sciences, Inc., Ipsen SA, Jazz Pharmaceuticals plc, Lantheus Holdings, Inc., Leadient BioSciences Inc., Mallinckrodt Pharmaceuticals, Merck & Co., Inc., Nano spectra Biosciences, Inc., Novo Nordisk A/S, OSARTIS GmbH, Pacira BioSciences Inc., Pfizer Inc., Sanofi S.A., Taiwan Liposome Company, Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceuticals Ltd., UCB SA, and Zimmer Biomet Holdings, Inc..

Market Segmentation & Coverage

This research report categorizes the Nanomedicine Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Molecule Type
    • Nanodevices
    • Nanoparticles
      • Dendrimers
      • Hydrogel Nanoparticles
      • Inorganic Nanoparticles
      • Liposomes
      • Metal & Metal Oxide Nanoparticles
      • Polymers & Polymer Drug Conjugates
    • Nanoshells
    • Nanotubes
  • Modality
    • Diagnostics
    • Treatment
  • Application
    • Diagnostic Imaging
    • Drug Delivery
    • Implants
    • Regenerative Medicine
    • Vaccines
  • Indication
    • Clinical Cardiology
    • Clinical Oncology
    • Immunology
    • Infectious Diseases
    • Neurology
    • Ophthalmology
    • Orthopedics
    • Urology
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Nanomedicine Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Nanomedicine Market?

3. What are the technology trends and regulatory frameworks in the Nanomedicine Market?

4. What is the market share of the leading vendors in the Nanomedicine Market?

5. Which modes and strategic moves are suitable for entering the Nanomedicine Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Nanomedicine Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of chronic diseases and need for efficient treatment
      • 5.1.1.2. Utilization of nanomedicine technology for personalized medicine
      • 5.1.1.3. Applications in vitro diagnostics and in vivo imaging
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of development and commercialization of nanomedicine
    • 5.1.3. Opportunities
      • 5.1.3.1. Strategic alliances for development of novel nanomedicine
      • 5.1.3.2. Favorable funding landscape for research and development of nanomedicine
    • 5.1.4. Challenges
      • 5.1.4.1. Limited availability of clinical evidence
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Nanomedicine Market, by Molecule Type

  • 6.1. Introduction
  • 6.2. Nanodevices
  • 6.3. Nanoparticles
    • 6.4.1. Dendrimers
    • 6.4.2. Hydrogel Nanoparticles
    • 6.4.3. Inorganic Nanoparticles
    • 6.4.4. Liposomes
    • 6.4.5. Metal & Metal Oxide Nanoparticles
    • 6.4.6. Polymers & Polymer Drug Conjugates
  • 6.4. Nanoshells
  • 6.5. Nanotubes

7. Nanomedicine Market, by Modality

  • 7.1. Introduction
  • 7.2. Diagnostics
  • 7.3. Treatment

8. Nanomedicine Market, by Application

  • 8.1. Introduction
  • 8.2. Diagnostic Imaging
  • 8.3. Drug Delivery
  • 8.4. Implants
  • 8.5. Regenerative Medicine
  • 8.6. Vaccines

9. Nanomedicine Market, by Indication

  • 9.1. Introduction
  • 9.2. Clinical Cardiology
  • 9.3. Clinical Oncology
  • 9.4. Immunology
  • 9.5. Infectious Diseases
  • 9.6. Neurology
  • 9.7. Ophthalmology
  • 9.8. Orthopedics
  • 9.9. Urology

10. Americas Nanomedicine Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Nanomedicine Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Nanomedicine Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. FPNV Positioning Matrix
  • 13.2. Market Share Analysis, By Key Player
  • 13.3. Competitive Scenario Analysis, By Key Player

14. Competitive Portfolio

  • 14.1. Key Company Profiles
    • 14.1.1. AMAG Pharmaceuticals, Inc.
    • 14.1.2. Amgen Inc.
    • 14.1.3. Arrowhead Pharmaceuticals, Inc.
    • 14.1.4. Bausch Health Companies Inc.
    • 14.1.5. Bayer Healthcare
    • 14.1.6. Biogen Inc.
    • 14.1.7. Bristol-Myers Squibb Company
    • 14.1.8. Celgene Corporation
    • 14.1.9. Eisai Co Ltd
    • 14.1.10. F. Hoffmann-La Roche AG
    • 14.1.11. Galen Ltd
    • 14.1.12. General Electric Company
    • 14.1.13. Gilead Sciences, Inc.
    • 14.1.14. Ipsen SA
    • 14.1.15. Jazz Pharmaceuticals plc
    • 14.1.16. Lantheus Holdings, Inc.
    • 14.1.17. Leadient BioSciences Inc.
    • 14.1.18. Mallinckrodt Pharmaceuticals
    • 14.1.19. Merck & Co., Inc.
    • 14.1.20. Nano spectra Biosciences, Inc.
    • 14.1.21. Novo Nordisk A/S
    • 14.1.22. OSARTIS GmbH
    • 14.1.23. Pacira BioSciences Inc.
    • 14.1.24. Pfizer Inc.
    • 14.1.25. Sanofi S.A.
    • 14.1.26. Taiwan Liposome Company, Ltd.
    • 14.1.27. Takeda Pharmaceutical Company Limited
    • 14.1.28. Teva Pharmaceuticals Ltd.
    • 14.1.29. UCB SA
    • 14.1.30. Zimmer Biomet Holdings, Inc.
  • 14.2. Key Product Portfolio

15. Appendix

  • 15.1. Discussion Guide
  • 15.2. License & Pricing